Journal
FRONTIERS IN PHARMACOLOGY
Volume 11, Issue -, Pages -Publisher
FRONTIERS MEDIA SA
DOI: 10.3389/fphar.2020.580073
Keywords
Alisol A; AMPK/SIRT1 pathway; anti-atherogenesis; anti-inflammation; PPAR alpha/delta
Categories
Funding
- Shanghai science and technology innovation action plan biomedical science and technology [12401901300]
Ask authors/readers for more resources
Alismatis Rhizoma (zexie), an herb used in traditional Chinese medicine, exhibits hypolipemic, anti-inflammation and anti-atherosclerotic activities. Alisol A is one of the main active ingredients in Alismatis Rhizoma extract. In this study, we investigate the role of alisol A in anti-atherosclerosis (AS). Our study demonstrated that alisol A can effectively inhibit the formation of arterial plaques and blocked the progression of AS in ApoE(-/-) mice fed with high-fat diet and significantly reduced the expression of inflammatory cytokins in aorta, including ICAM-1, IL-6, and MMP-9. In addition, we found that alisol A increased the expression of PPAR alpha and PPAR delta proteins in HepG2 cells and in liver tissue from ApoE(-/-) mice. Alisol A activated the AMPK/SIRT1 signaling pathway and NF-kappa B inhibitor I kappa B alpha in HepG2 cells. Our results suggested that alisol A is a multi-targeted agent that exerts anti-atherosclerotic action by regulating lipid metabolism and inhibiting inflammatory cytokine production. Therefore, alisol could be a promising lead compound to develop drugs for the treatment of AS.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available